William Garland

DR. WILLIAM GARLAND is the CEO of AngioGenex, Inc., a New York City-based biotechnology company. He was the Vice President of Development for Lpath Therapeutics in San Diego, Calif., from 2003 to 2008, and the Vice President of Scientific Affairs for Atairgin Technologies in Irvine, Calif., from 2001 to 2002. Prior to joining Atairgin, Dr. Garland was the Executive Vice President of Pharmaceutical Development with Centaur Pharmaceuticals, a Silicon Valley biopharmaceutical company, from 1995 to 2001. At Centaur, Dr. Garland was responsible for all aspects of preclinical drug testing, the design and execution of clinical studies, Q.A., Q.C., pilot manufacturing, and interactions with the FDA and international drug regulatory authorities. Dr. Garland was with Hoffmann-La Roche in Nutley, N.J., from 1974 to 1994, most recently as Senior Director and U.S. Head of International Project Management. During his 20-year tenure at Roche, Dr. Garland managed groups consisting of as many as 100 scientific and administrative personnel. He received a B.S. in chemistry from the University of San Francisco in 1968 and a Ph.D. in medicinal chemistry from the University of Washington in 1974. Dr. Garland has authored or co-authored more than 100 scientific publications.